4 June 2019
BMA House, London


View Programme

Book Now


HSJ Life Sciences Forum
Innovating to deliver improved patient services and outcomes

BMA House, London • 4 June 2019


09:00 Registration & Refreshments

Chair’s Opening Remarks

Alastair McLellan, Editor, HSJ


Opening Keynote Plenary
Baroness Blackwood, Parliamentary Under Secretary of State for Health, Department of Health and Social Care


Panel Discussion: What the NHS long-term plan means for industry
Dr Sam Roberts, Director of Innovation, Research and Life Sciences Group, NHS England

James Roach, Director, West Essex ICP

Mark Duman, Chief Patient Officer, MD Healthcare Consultants


Morning Refreshments & Networking


Innovation & Digital

Governance & Regulation

Using data to support innovation

(Courtyard Suite)

  • Learn how Local Health and Care Records (LHCRE) are being used in regional hubs
  • Find out how new digital technologies will be evaluated in future
  • Gain insight into how data flows are being utilised and what rules are being enforced

Harry Hemingway, Professor of Clinical Epidemiology, University College London Institute of Informatics

Understanding industry’s role in STPs and ICSs

(Great Hall)

  • Hear first-hand the plans being created at a local level through the STP process
  • Learn what challenges STPs are facing and how industry could support
  • Take part in a discussion to find out how industry can better support STPs

Dr Phil Richardson, Chief System Integration Officer, Dorset ICS


Networking Lunch


Unleashing the potential of genomics and personalised medicine

(Great Hall)

  • Receive an update on 100,000 Genomes project
  • How the is project making the UK an attractive investment destination for life sciences
  • Learn how data is being used to accelerate treatments and enable efficient drug research

Joanne Hackett, Chief Commercial Officer, Genomics England
Professor Dame Sue Hill, Chief Scientific Officer, NHS England
Sue Bailey, Strategic Partnership & Early Asset Director, BMS

Removing barriers: evolving the role of regulation

(Courtyard Suite)

  • Understand how the role of MHRA is changing and what this means for industry
  • Learn about the successes from the NICE fast track programme
  • Find out how NHS England’s commercial team has improved access to new drugs

Meindert Boysen, Centre for Health Technology Evaluation Director, NICE


Afternoon Refreshments & Networking


Voluntary scheme for branded medicines pricing and access: What the final agreement means for industry and the NHS

Steve Oldfield, Chief Commercial Officer, Department of Health and Social Care
Louise Houson, Managing Director UK, MSD


Specialised Commissioning: Improving access to new treatments in rare diseases

Blake Dark, NHS Commercial Medicines Director, NHS England


Panel Discussion: Next steps for implementing the Life Sciences Industrial Strategy in post-Brexit Britain

Nicole Mather, Partner, Life Sciences Lead, IBM GBS London

Mike Thompson, Chief Executive, ABPI

James Roach, Director, West Essex ICP


Chair’s Closing Remarks

Alastair McLellan, Editor, HSJ


Networking Reception

By continuing to use the site you agree to our cookies policy. Accept